A Phase III Study of Interferon-Refractory Patients With BCR/ABL(+) Chronic Myelogenous Leukemia (CML) Treated With Homoharringtonine [omacetaxine mepesuccinate] (NSC 141633) vs. Hydroxyurea [hydroxycarbamide]

Trial Profile

A Phase III Study of Interferon-Refractory Patients With BCR/ABL(+) Chronic Myelogenous Leukemia (CML) Treated With Homoharringtonine [omacetaxine mepesuccinate] (NSC 141633) vs. Hydroxyurea [hydroxycarbamide]

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2015

At a glance

  • Drugs Hydroxycarbamide (Primary) ; Omacetaxine mepesuccinate (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jun 2011 Planned end date (May 2001) added as reported by ClinicalTrials.gov.
    • 01 Apr 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 10 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top